nu2058 and cyc 202

nu2058 has been researched along with cyc 202 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ferguson, M; Fersht, A; Finlan, L; Hupp, TR; Ibbotson, S; Luciani, MG; Rankin, EM	1

Other Studies

1 other study(ies) available for nu2058 and cyc 202

Article	Year
The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death. Cell cycle (Georgetown, Tex.), 2004, Volume: 3, Issue:1 Topics: Antineoplastic Agents; Binding Sites; CDC2-CDC28 Kinases; Cell Death; Cyclin A; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Guanine; Humans; Mutation; Peptide Fragments; Phosphorylation; Protein Binding; Purines; Roscovitine; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2004

Article

Year

The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.

Cell cycle (Georgetown, Tex.), 2004, Volume: 3, Issue:1

Topics: Antineoplastic Agents; Binding Sites; CDC2-CDC28 Kinases; Cell Death; Cyclin A; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Guanine; Humans; Mutation; Peptide Fragments; Phosphorylation; Protein Binding; Purines; Roscovitine; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2004